Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash provided by (used for) operating activities
Net income (loss)	$ 314	$ 110
Depreciation and amortization	285	274
Deferred and prepaid income taxes	19	(75)
Stock-based compensation expense	55	52
Net loss (gain) on investments and notes receivable	31	20
Contingent consideration net expense (benefit)	12	12
Inventory step-up amortization	0	17
Gain (Loss) on Extinguishment of Debt	0	194
Other, net	(2)	19
Trade accounts receivable	(86)	(66)
Inventories	(185)	(108)
Other assets	(41)	(140)
Accounts payable, accrued expenses and other liabilities	(211)	(368)
Cash provided by (used for) operating activities	190	(58)
Investing activities:
Purchases of property, plant and equipment and internal use software	(111)	(121)
Proceeds from sale of property, plant and equipment	3	8
Payments for acquisitions of businesses, net of cash acquired	(375)	(1,471)
Proceeds from royalty rights	9	19
Proceeds from (payments for) investments and acquisitions of certain technologies	(10)	(10)
Cash provided by (used for) investing activities	(484)	(1,574)
Financing activities:
Payment of contingent consideration previously established in purchase accounting	(34)	(20)
Payments for royalty rights	(34)	(39)
Payments on short-term borrowings	0	(250)
Net increase (decrease) in commercial paper	0	223
Payments on long-term borrowings and debt extinguishment costs	0	(3,184)
Proceeds from long-term borrowings, net of debt issuance costs	0	3,271
Cash dividends paid on preferred stock	(14)	(14)
Cash used to net share settle employee equity awards	(50)	(46)
Proceeds from issuances of common stock pursuant to employee stock compensation and purchase plans	63	52
Cash provided by (used for) financing activities	(69)	(6)
Effect of foreign exchange rates on cash	0	0
Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents	(363)	(1,639)
Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period	1,126	2,168
Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period	763	529
Supplemental Information
Stock-based compensation expense	55	52
Non-cash impact of transferred royalty rights	$ (9)	$ (19)